Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Qingjuan Zuo"'
Autor:
Zhongli Wang, Tingting Zhang, Xinyu Wang, Jianlong Zhai, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Yifang Guo
Publikováno v:
Renal Failure, Vol 46, Iss 2 (2024)
Objective The aim of this study was to investigate the potential importance of complement system activation, with particular emphasis on the complement alternative pathway (AP), in the pathogenesis of hypertensive renal damage.Methods Serum complemen
Externí odkaz:
https://doaj.org/article/3ae8cd875aaa4a5793f5b4afb573a1ab
Autor:
Lili He, Qingjuan Zuo, Sai Ma, Guorui Zhang, Zhongli Wang, Tingting Zhang, Jianlong Zhai, Yifang Guo
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Purpose To investigate the effects of canagliflozin (20 mg/kg) on Dahl salt-sensitive (DSS) rat gut microbiota and salt-sensitive hypertension-induced kidney injury and further explore its possible mechanism.Methods Rats were fed a high-salt diet to
Externí odkaz:
https://doaj.org/article/58889af7424a453b90e6376a55939d37
Autor:
Jianlong Zhai, Zhongli Wang, Tingting Zhang, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Xinyu Wang, Yifang Guo
Publikováno v:
Journal of International Medical Research, Vol 51 (2023)
Objectives This study assessed the antifibrotic effects of canagliflozin, with or without irbesartan, on renal injury in Dahl salt-sensitive (SS) rats fed a high-salt (HS) diet. Methods After the preconditioning stage, Dahl SS rats (n = 47) were divi
Externí odkaz:
https://doaj.org/article/360764eedd3d4ec9b3fa071171eb2862
Autor:
Qingjuan Zuo, Lili He, Sai Ma, Guorui Zhang, Jianlong Zhai, Zhongli Wang, Tingting Zhang, Yan Wang, Yifang Guo
Publikováno v:
Cardiovascular Innovations and Applications, Vol 9, Iss 1, p 981 (2024)
Purpose: This study was aimed at investigating the effect of canagliflozin (Cana) on atherosclerosis and further exploring its potential mechanism. Methods: ApoE −/− mice were fed a Western diet (WD) and randomly divided into a WD group and WD+Ca
Externí odkaz:
https://doaj.org/article/1cfa0b874e2c4250808162dfcdcc56d6
Autor:
Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Zhongli Wang, Tingting Zhang, Jianlong Zhai, Yifang Guo
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The aim of the study was to investigate the protective effect of canagliflozin (CANA) on myocardial metabolism and heart under stress overload and to further explore its possible molecular mechanism.Methods: High-salt diet was used to ind
Externí odkaz:
https://doaj.org/article/0108296893db448fa1ccaf285cbadd28
Publikováno v:
Cardiovascular Innovations and Applications, Vol 7, Iss 1, p 987 (2023)
Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to ameliorate major adverse cardiovascular events in patients with heart failure with preserved ejection fraction (HFpEF), but the exact mechanism is unknown. Ferroptosis is a fo
Externí odkaz:
https://doaj.org/article/e507d801aa52491284c3f15d5c495f63
Autor:
Zhongli Wang, Jianlong Zhai, Tingting Zhang, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Yan Wang, Yifang Guo
Publikováno v:
Biochemical and Biophysical Research Communications. 653:53-61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e0bc4c4fe87abf94f5ab7e6c4540373
https://doi.org/10.1016/j.bbrc.2023.01.084
https://doi.org/10.1016/j.bbrc.2023.01.084
Autor:
Qingjuan Zuo, Guorui Zhang, Lili He, Sai Ma, Huijuan Ma, Jianlong Zhai, Zhongli Wang, Tingting Zhang, Yan Wang, Yifang Guo
Publikováno v:
Drug Design, Development and Therapy. 16:4161-4177
Qingjuan Zuo,1,2 Guorui Zhang,1,3 Lili He,2 Sai Ma,4 Huijuan Ma,5 Jianlong Zhai,6 Zhongli Wang,7 Tingting Zhang,2 Yan Wang,2 Yifang Guo1,2 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Peopleâs Republic of China; 2Dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::982222bd7386a9d41e448489d1906bb3
https://doi.org/10.2147/dddt.s388823
https://doi.org/10.2147/dddt.s388823
Autor:
Jianlong Zhai, Zhongli Wang, Tingting Zhang, Lili He, Sai Ma, Qingjuan Zuo, Guorui Zhang, Xinyu Wang, Yifang Guo
Hypertension is one of the major contributors to cardiovascular and chronic kidney disease (CKD). Sodium-glucose cotransporter 2 (SGLT2) inhibitors and angiotensin receptor blockers (ARBs) have become the preferred treatment for patients with CKD. Ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc5ce0215849eca63e65d627b5658716
https://doi.org/10.1101/2022.12.27.522015
https://doi.org/10.1101/2022.12.27.522015
Autor:
Guorui Zhang, Qingjuan Zuo, Sai Ma, Lili He, Zhongli Wang, Jianlong Zhai, Tingting Zhang, Yan Wang, Yifang Guo
Background Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular mortality in patients. We studied the effect of canagliflozin on cardiac remodeling and myocardial metabolism in a rat model of heart failure with preserved ejection fraction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e1f418f7ceb0d599b4aa1605dbee597
https://doi.org/10.21203/rs.3.rs-1886973/v1
https://doi.org/10.21203/rs.3.rs-1886973/v1